�Ӱ���Ƶ

‍Harwell, Oxford, May 1, 2025, (�Ӱ���Ƶ), a platform biotech companydeveloping novel mitochondrial-targeted persulfide modifiers, today announcesthe appointment of Xavier Jacq as Chief Scientific Officer (CSO).

Xavier is a world-class scientistwith extensive experience in small molecule drug development and mitochondrialbiology. He was most recently CSO at Moa Technologies in Oxford. Xavierpreviously held scientific leadership positions at Almac and MissionTherapeutics, and project leadership positions at Kudos and Sanofi. He has beena company founder, helping raise investment, building labs and drug discoveryteams from scratch, and helping companies successfully exit throughacquisition.

The new CSO significantlystrengthens the �Ӱ���Ƶ team as it builds towards clinical candidate nominationin its lead indication of the treatment of obesity and also develops a pipelineof discrete novel persulfide modifiers for a range of degenerative diseases.

“Welcoming Xavier to �Ӱ���Ƶ cementsour position as the leading biotech company developing mitochondrial-targetedtherapeutics,” said Jon Rees, CEO, �Ӱ���Ƶ.

“�Ӱ���Ƶ is developing an innovative technology to restoremitochondrial metabolic pathways that are suppressed in a number of pathologiesand in ageing. The prospect of being able to contribute to restoring metabolicfunction for patients with unmet medical needs is such an exciting opportunitythat I had to join,” saidXavier Jacq, CSO, �Ӱ���Ƶ. “�Ӱ���Ƶ is a company with an enthusiastic andexperienced team. This was also an essential factor in my decision to join�Ӱ���Ƶ. We now have the potential to make a significant difference a largenumber of patients with degenerative diseases.”��